Draft Guidance for Clinical Investigators, Industry, and FDA Staff: Financial Disclosure by Clinical Investigators; Availability

Короткий зміст

The Food and Drug Administration (FDA) is announcing the availability of a draft guidance entitled "Guidance for Clinical Investigators, Industry, and FDA Staff: Financial Disclosure by Clinical Investigators." This draft guidance is intended to assist clinical investigators, industry, and FDA staff in interpreting and complying with the regulations governing financial disclosure by clinical investigators. This guidance provides FDA's responses to the most frequently asked questions regarding financial disclosure by clinical investigators.